查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2149758

PCR技術市場：依技術、產品、應用、最終用戶和地區分類－全球預測至2031年

PCR Technologies Market by Technology, Product, Application, End User and Region - Global forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 293 Pages | 訂單完成後即時交付

價格

PCR技術市場預計將從2026年的155.5億美元成長到2031年的214.3億美元，2026年至2031年的複合年成長率為6.6%。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（10億美元）
部分 產品、技術、應用、最終用戶和地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

在精密儀器和高保真度酶的推動下，PCR技術市場正朝著更高的效率、準確性、靈敏度和多功能性方向發展。即時PCR(qPCR) 可實現即時監測和定量分析，而RT-PCR則支援RNA分析、基因表現研究和病毒檢測。數位PCR (dPCR) 在需要極高準確性和靈敏度進行絕對定量的應用中日益重要，進一步拓展了PCR在科學研究和診斷領域的應用範圍。

PCR技術市場-IMG1

“預計到2025年，qPCR將佔據最大的市場佔有率。”

由於qPCR在診斷和研究領域擁有成熟的應用經驗，尤其是在需要精確定量分析的領域，預計它將佔據PCR技術市場最大的佔有率。 qPCR結合了PCR擴增和使用螢光染料及探針的即時監測，能夠對每個循環中的目標DNA進行定量分析。其廣泛的效用以及在分子診斷和研究領域的既有地位，都推動了qPCR的廣泛普及。

“預計診斷檢查室將佔據最大的市場佔有率。”

在對快速、高靈敏度和高精度分子檢測日益成長的需求推動下，診斷檢查室預計仍將是PCR技術的最大終端用戶。 PCR廣泛應用於感染疾病檢測、基因檢測、腫瘤學和疾病監測。檢測量的不斷成長和對高通量工作流程日益成長的需求進一步推動了其應用。向自動化、標準化和整合化的分子檢測系統的轉變也促進了PCR在診斷檢查室中的應用。

預計到2026年，北美仍將保持PCR技術最大的市場佔有率，這得益於其先進的醫療保健基礎設施、分子診斷技術的積極應用以及在基因組學、精準醫療和生命科學研究領域的大量投資。該地區也受益於主要PCR技術供應商的存在，以及PCR技術在臨床診斷、傳染病檢查、腫瘤學和基因檢測領域的廣泛應用。強大的研發能力和先進PCR平台的持續發展進一步鞏固了北美的市場領導地位。

本報告中提及的主要公司如下：

  • 按公司類型分類：一級供應商 - 30%，二級供應商 - 42%，三級供應商 - 28%
  • 依職位：首席等級－10%，總監等級－14%，其他－76%
  • 按地區分類：北美 - 40%，歐洲 - 30%，亞太地區 - 22%，世界其他地區 - 8%。

調查範圍

本研究報告按產品、材料、最終用戶和地區對市場進行分析。報告涵蓋市場擴張的促進因素，分析了當前的行業前景和挑戰，並提供了有關競爭格局的詳細資訊，包括領先企業和中小企業。該報告還對五個區域和微觀市場進行了分析，並估算了每個細分市場的收入。

購買本報告的理由

本報告為市場領導和新參與企業提供了整體市場及其細分市場收入預測的寶貴資訊。它幫助相關人員了解競爭格局，更有效地進行業務定位，並制定合適的打入市場策略。此外，該報告還深入分析了市場動態，包括關鍵的市場促進因素和挑戰。

本報告就以下幾點提供了富有洞察力的數據：

  • 市場滲透率：對PCR技術市場主要參與者提供的產品系列進行詳細分析。
  • 產品開發/創新：對PCR技術市場主要參與者提供的產品系列進行詳細分析。
  • 市場發展：有關盈利成長領域的實用數據
  • 市場多元化：PCR技術市場近期趨勢與進展詳情
  • 競爭分析：對主要競爭對手的產品、成長策略、收入預測和市場類別進行全面評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

  • PCR技術市場概覽
  • 區域PCR技術市場
  • 亞太地區：依國家及產品分類的PCR技術市場
  • PCR技術市場區域概覽

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 一級/二級/三級主要公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
    • 新進入者的威脅
    • 替代品的威脅
    • 供應商的議價能力
    • 買方的議價能力
    • 競爭公司之間的競爭
  • 宏觀經濟展望
    • 總體經濟指標
    • GDP趨勢與預測
    • 全球PCR技術市場趨勢
  • 價值鏈分析
    • 研究與開發
    • 原料採購和生產
    • 分銷、行銷和銷售以及售後服務
  • 生態系分析
  • 價格分析
    • 主要廠商即時PCR儀參考價（2025年）
    • 各地區以PCR為基礎的產品參考價格（2023-2025年）
  • 貿易數據分析
    • HS編碼3822的進口數據
    • 出口資料（HS編碼3822）
  • 重大會議和活動（2026-2027）
  • 影響客戶業務的趨勢和變化
  • 投資和資金籌措場景
  • 案例研究分析
    • 利用數位PCR技術對遊離DNA中的KRAS突變進行多重檢測。
    • 基於 PCR 的鮑曼鮑氏不動桿菌鑑定有助於有針對性的感染疾病控制。
  • 美國關稅對PCR技術市場的影響
    • 主要關稅稅率
    • 價格影響分析

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 主要技術
    • 聚合酵素連鎖反應熱迴圈儀
    • 即時定量PCR
    • 可攜式和即時PCR
  • 互補技術
    • 次世代定序
    • 微陣列
    • 晶片實驗室設備
    • 機器人與自動化
  • 專利分析
  • 人工智慧/生成式人工智慧對PCR技術市場的影響
    • 主要應用場景和市場潛力
    • PCR技術市場中各公司的最佳實踐
    • 人工智慧/生成式人工智慧在PCR技術市場引入案例研究
    • 相互關聯的生態系統及其對市場參與者的影響
    • 客戶對PCR技術市場中人工智慧/基因工程人工智慧應用的準備情況
  • 成功案例和實際應用

第7章：顧客趨勢與購買行為

  • 決策流程
  • 採購過程中的關鍵相關人員和評估標準
    • 採購過程中的關鍵相關人員
    • 主要購買標準
  • 實施障礙和內部挑戰
  • 各種應用中尚未滿足的需求
  • 監理情勢
    • 監管分析

第8章 PCR技術市場：依產品分類

  • 試劑和耗材
  • 裝置
  • 軟體和服務

第9章 PCR技術市場：依方法分類

  • 即時PCR
  • 常規PCR
  • 數位PCR
  • 逆轉錄PCR
  • 熱啟動PCR
  • 多重PCR
  • 其他PCR技術

第10章 PCR技術市場：依應用分類

  • 診斷用途
  • 基因分型
  • 核酸檢測
  • 基因表現分析
  • 核酸合成
  • 基因序列測定
  • 環境領域的應用
  • 標準材料的驗證和檢驗
  • 其他用途

第11章：PCR技術市場：依最終用戶分類

  • 醫院檢查室
  • 診斷檢查室
  • 學術機構及政府機構
  • 製藥和生物技術公司
  • 其他最終用戶

第12章：PCR技術市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲
  • 中東和非洲
    • 海灣合作理事會國家
    • 其他中東和非洲地區

第13章 競爭格局

  • 主要參與企業的策略/優勢
    • PCR技術市場主要參與者所採取的策略概述。
  • 收入分析（2022-2025）
  • 市佔率分析（2025 年）
    • 主要公司PCR設備市場佔有率（2025年）
    • PCR試劑和耗材市場佔有率（按主要公司分類，2025年）
    • 2025年全球PCR軟體和服務市場佔有率（按主要公司分類）
  • 企業估值矩陣：以主要公司分類，2025 年
    • 明星公司
    • 新興領導者
    • 玩家種類繁多
    • 參與企業
    • 企業企業發展：主要公司，2025 年
  • 公司估值矩陣：新創企業/中小企業，2025 年
    • 先進公司
    • 應對力的公司
    • 充滿活力的公司
    • 起始點
    • 企業標竿分析：新創企業/中小企業，2025 年
  • 企業估值與財務指標，2025 年
  • 產品和品牌比較
  • 競爭格局
    • 產品上市及核准
    • 交易
    • 業務拓展

第14章：公司簡介

  • 大公司
    • THERMO FISHER SCIENTIFIC INC.
    • F. HOFFMANN-LA ROCHE LTD.
    • AGILENT TECHNOLOGIES, INC.
    • BIO-RAD LABORATORIES, INC.
    • QIAGEN
    • DANAHER CORPORATION
    • BBOTT
    • TAKARA BIO INC.
    • ANALYTIK JENA GMBH+CO. KG
    • EPPENDORF SE
    • MERCK KGAA
    • BIONEER CORPORATION
    • REVVITY
    • BECTON, DICKINSON AND COMPANY
    • BIOMERIEUX
    • STANDARD BIOTOOLS
    • HOLOGIC, INC.
    • LONZA
    • ILLUMINA, INC.
    • SANSURE BIOTECH INC.
  • 其他主要公司
    • PROMEGA CORPORATION
    • LIMING BIO
    • TRANSGEN BIOTECH CO., LTD.
    • DAAN GENE CO., LTD.
    • BIOBASE GROUP
    • NIPPON GENETICS EUROPE
    • STILLA
    • GENSCRIPT
    • NEW ENGLAND BIOLABS

第15章：調查方法

第16章附錄

Product Code: AST 7880

The PCR technologies market is projected to reach USD 21,430 million by 2031, up from USD 15,550 million in 2026, at a CAGR of 6.6% during 2026-2031.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct, Technique, Application, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and Middle East & Africa

The PCR technologies market is evolving toward higher efficiency, accuracy, sensitivity, and versatility, driven by advances in sophisticated instrumentation and high-fidelity enzymes. Real-time PCR (qPCR) enables real-time monitoring and quantitative analysis, while RT-PCR supports RNA analysis, gene expression studies, and viral detection. Digital PCR (dPCR) is gaining importance for applications requiring highly precise and sensitive absolute quantification, further broadening PCR's applications across research and diagnostics.

PCR Technologies Market - IMG1

"qPCR to account for largest market share in 2025."

qPCR is expected to hold the largest share of the PCR technologies market due to its established use in diagnostics and research, where precise quantification is required. By combining PCR amplification with real-time monitoring using fluorescent dyes or probes, qPCR enables quantitative analysis of target DNA at each cycle. Its broad utility and established role in molecular diagnostics and research support its widespread adoption.

"Diagnostic laboratories to hold largest share in the market."

Diagnostic laboratories are expected to remain the largest end users of PCR technologies, driven by the growing need for rapid, sensitive, and accurate molecular testing. PCR is widely used for infectious disease detection, genetic testing, oncology, and disease monitoring. Rising testing volumes and demand for high-throughput workflows further support adoption. The shift toward automated, standardized, and integrated molecular testing systems is also strengthening PCR utilization in diagnostic laboratories.

North America is expected to retain the largest share of the PCR technologies market in 2026, supported by advanced healthcare infrastructure, strong adoption of molecular diagnostics, and substantial investments in genomics, precision medicine, and life-science research. The region also benefits from major PCR technology providers and the widespread use of PCR in clinical diagnostics, infectious disease testing, oncology, and genetic testing. Strong research capabilities and ongoing development of advanced PCR platforms further reinforce North America's market leadership.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1-30%, Tier 2-42%, and Tier 3- 28%
  • By Designation: C-level-- 10%, Director-level-14%, and Others-76%
  • By Region: North America-40%, Europe-30%, Asia Pacific-22%, Rest of the World - 8%.

Prominent players in the PCR technologies market include F. Hoffman-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), QIAGEN (Germany), Sansure Biotech Inc. (China), Becton, Dickinson and Company (US), Analytik Jena AG (Germany), Takara Bio, Inc. (Japan), Agilent Technologies, Inc. (US), Standard Biotools (US), Danaher Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Illumina, Inc. (US), Bioneer Corporation (South Korea), PerkinElmer Inc. (US), and Hologic Inc. (US).

Research Coverage

The research report examines the market by product, material end-users, and geography. This research covers factors that are driving market expansion, analyzes current industry prospects and challenges, and provides specifics on the competitive landscape, including market leaders and small and medium enterprises. This research also estimates the revenue of different market segments by considering five regions and micro-market analysis.

Reasons to Buy the Report

The report will provide market leaders and new entrants with valuable information on revenue estimates for the overall market and its subsegments. It will help stakeholders understand the competitive landscape, enabling them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.

This report provides insightful data on the following pointers:

  • Market Penetration: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
  • Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the PCR technologies market
  • Market Development: Insightful data on profitable developing areas
  • Market Diversification: Details about recent developments and advancements in the PCR technologies market
  • Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN PCR TECHNOLOGIES MARKET
  • 2.4 HIGH-GROWTH SEGMENTS

3 PREMIUM INSIGHTS

  • 3.1 PCR TECHNOLOGIES MARKET OVERVIEW
  • 3.2 PCR TECHNOLOGIES MARKET, BY REGION
  • 3.3 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY AND PRODUCT
  • 3.4 GEOGRAPHIC SNAPSHOT OF PCR TECHNOLOGIES MARKET

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Laboratories Increasing outbreaks of infectious diseases/viral persistence
      • 4.2.1.2 Development of miniaturized and portable point-of-care testing devices
      • 4.2.1.3 High demand for technologically advanced molecular diagnostics
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 Premium product pricing
      • 4.2.2.2 Dearth of skilled healthcare professionals
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increased investments in laboratory infrastructure
      • 4.2.3.2 Rising number of applications in rare sequence detection
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Technical limitations
      • 4.2.4.2 Increased pricing pressure on market players
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF SUPPLIERS
    • 5.1.4 BARGAINING POWER OF BUYERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 MACROECONOMIC INDICATORS
    • 5.2.3 GDP TRENDS AND FORECAST
    • 5.2.4 TRENDS IN GLOBAL PCR TECHNOLOGIES MARKET
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & DEVELOPMENT
    • 5.3.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING
    • 5.3.3 DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 INDICATIVE PRICING REAL-TIME PCR INSTRUMENTS, BY KEY PLAYER, 2025
    • 5.5.2 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
      • 5.5.2.1 North America
      • 5.5.2.2 Europe
      • 5.5.2.3 Asia Pacific
      • 5.5.2.4 Rest of the World
  • 5.6 TRADE DATA ANALYSIS
    • 5.6.1 IMPORT DATA FOR HS CODE 3822
    • 5.6.2 EXPORT DATA (HS CODE 3822)
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT AND FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 MULTIPLEX DETECTION OF KRAS MUTATIONS IN CELL-FREE DNA USING DIGITAL PCR
    • 5.10.2 PCR-BASED IDENTIFICATION OF ACINETOBACTER BAUMANNII SUPPORTS TARGETED INFECTION MANAGEMENT
  • 5.11 IMPACT OF US TARIFFS - PCR TECHNOLOGIES MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
      • 5.11.3.1 Impact on countries/regions
      • 5.11.3.2 Impact on end-users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACTS, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY TECHNOLOGIES
    • 6.1.1 THERMAL CYCLERS
    • 6.1.2 REAL-TIME QUANTITATIVE PCR
    • 6.1.3 PORTABLE AND POINT-OF-CARE PCR
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 NEXT-GENERATION SEQUENCING
    • 6.2.2 MICROARRAYS
    • 6.2.3 LAB-ON-A-CHIP DEVICES
    • 6.2.4 ROBOTICS AND AUTOMATION
  • 6.3 PATENT ANALYSIS
  • 6.4 IMPACT OF AI/GEN AI ON PCR TECHNOLOGIES MARKET
    • 6.4.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.4.2 BEST PRACTICES FOLLOWED BY COMPANIES IN PCR TECHNOLOGIES MARKET
    • 6.4.3 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION IN PCR TECHNOLOGIES MARKET
    • 6.4.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.4.5 CLIENT'S READINESS TO ADOPT AI/GEN AI IN PCR TECHNOLOGIES MARKET
  • 6.5 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

  • 7.1 DECISION-MAKING PROCESS
  • 7.2 KEY STAKEHOLDERS IN BUYING PROCESS AND EVALUATION CRITERIA
    • 7.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 7.2.2 KEY BUYING CRITERIA
  • 7.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 7.4 UNMET NEEDS OF VARIOUS APPLICATIONS
  • 7.5 REGULATORY LANDSCAPE
    • 7.5.1 REGULATORY ANALYSIS
      • 7.5.1.1 North America
        • 7.5.1.1.1 US
        • 7.5.1.1.2 Canada
      • 7.5.1.2 Europe
      • 7.5.1.3 Asia Pacific
        • 7.5.1.3.1 Japan
        • 7.5.1.3.2 China
        • 7.5.1.3.3 India

8 PCR TECHNOLOGIES MARKET, BY PRODUCT

  • 8.1 INTRODUCTION
  • 8.2 REAGENTS AND CONSUMABLES
    • 8.2.1 INCREASING USE OF DPCR-BASED ANALYTICAL PROCEDURES IN GENETIC RESEARCH AND FORENSICS TO DRIVE MARKET
  • 8.3 INSTRUMENTS
    • 8.3.1 RISING AVAILABILITY OF TECHNOLOGICALLY ADVANCED AND INNOVATIVE PCR INSTRUMENTS TO FUEL MARKET GROWTH
  • 8.4 SOFTWARE AND SERVICES
    • 8.4.1 GROWING DEMAND FOR SPECIALIZED PCR ANALYSIS SOFTWARE IN ONCOLOGY STUDIES AND FORENSICS TO SPUR MARKET GROWTH

9 PCR TECHNOLOGIES MARKET, BY TECHNIQUE

  • 9.1 INTRODUCTION
  • 9.2 REAL-TIME PCR
    • 9.2.1 RISING ADOPTION OF REAL-TIME PCR AMONG RESEARCHERS AND HEALTHCARE PROFESSIONALS TO PROPEL MARKET GROWTH
  • 9.3 CONVENTIONAL PCR
    • 9.3.1 COST-EFFECTIVENESS AND EASE OF USAGE IN ROUTINE CLONING, GENOTYPING, AND MUTATION ANALYSIS TO FUEL MARKET GROWTH
  • 9.4 DIGITAL PCR
    • 9.4.1 FASTER RESULTS WITH LOWER MARGIN ERRORS TO DRIVE ADOPTION
  • 9.5 REVERSE TRANSCRIPTION PCR
    • 9.5.1 HIGHER SENSITIVITY FOR MEASURING CHANGES IN GENE EXPRESSION TO AUGMENT MARKET GROWTH
  • 9.6 HOT-START PCR
    • 9.6.1 BETTER REACTION SPECIFICITY WITH LOWER ERROR RATES TO FAVOR MARKET GROWTH
  • 9.7 MULTIPLEX PCR
    • 9.7.1 COST-EFFECTIVENESS AND HIGH THROUGHPUT TO AID MARKET GROWTH
  • 9.8 OTHER PCR TECHNIQUES

10 PCR TECHNOLOGIES MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 DIAGNOSTIC APPLICATIONS
    • 10.2.1 UNAVAILABILITY OF REIMBURSEMENTS FOR CLINICAL DIAGNOSTIC TESTS TO LIMIT MARKET GROWTH
  • 10.3 GENOTYPING
    • 10.3.1 LARGE TARGET PATIENT POPULATION FOR CANCER DIAGNOSIS TO AUGMENT MARKET GROWTH
  • 10.4 NUCLEIC ACID DETECTION
    • 10.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO BOOST MARKET GROWTH
  • 10.5 GENE EXPRESSION ANALYSIS
    • 10.5.1 INCREASED R&D FUNDING AND GRANTS FOR PCR TO FAVOR MARKET GROWTH
  • 10.6 NUCLEIC ACID SYNTHESIS
    • 10.6.1 INCREASED FOCUS ON PERSONALIZED AND PRECISE MEDICINES TO SUPPORT MARKET GROWTH
  • 10.7 GENETIC SEQUENCING
    • 10.7.1 TECHNOLOGICAL IMPROVEMENTS AND REDUCED COSTS OF SEQUENCING TO FUEL MARKET GROWTH
  • 10.8 ENVIRONMENTAL APPLICATIONS
    • 10.8.1 STRICT GOVERNMENT ENVIRONMENTAL POLICIES TO PROMOTE USE OF PCR
  • 10.9 STANDARD VALIDATION/VERIFICATION
    • 10.9.1 NEED FOR REGIONAL/GLOBAL VALIDATION FOR COMMERCIAL/NON-COMMERCIAL GUIDELINE FRAMING TO DRIVE MARKET
  • 10.10 OTHER APPLICATIONS

11 PCR TECHNOLOGIES MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 HOSPITAL LABORATORIES
    • 11.2.1 RISING PUBLIC AWARENESS OF ROUTINE CHECKUPS TO SUPPORT MARKET GROWTH
  • 11.3 DIAGNOSTIC LABORATORIES
    • 11.3.1 ESTABLISHMENT OF INDEPENDENT SPECIALIZED DIAGNOSTIC LABORATORIES TO PROPEL MARKET GROWTH
  • 11.4 ACADEMIC AND GOVERNMENT ORGANIZATIONS
    • 11.4.1 INCREASED GOVERNMENT SUPPORT FOR GENOME-BASED RESEARCH TO DRIVE MARKET
  • 11.5 PHARMA-BIOTECH COMPANIES
    • 11.5.1 INCREASING R&D INITIATIVES BY PHARMA-BIOTECH COMPANIES TO DRIVE ADOPTION OF PCR TECHNOLOGIES
  • 11.6 OTHER END USERS

12 PCR TECHNOLOGIES MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 US
      • 12.2.1.1 US to dominate North American PCR technologies market during study period
    • 12.2.2 CANADA
      • 12.2.2.1 Supportive government initiatives for genomics research to aid market growth
  • 12.3 EUROPE
    • 12.3.1 GERMANY
      • 12.3.1.1 Presence of well-established pharmaceutical and R&D industry to augment market growth
    • 12.3.2 FRANCE
      • 12.3.2.1 Increasing investments in life science R&D for infrastructural development to favor market growth
    • 12.3.3 UK
      • 12.3.3.1 Rising acceptance of genome-based diagnosis by clinicians and healthcare professionals to spur market growth
    • 12.3.4 ITALY
      • 12.3.4.1 Supportive government policies and high healthcare expenditure to boost market growth
    • 12.3.5 SPAIN
      • 12.3.5.1 Increasing funding for life science research and pharmaceutical drug development to boost market growth
    • 12.3.6 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 CHINA
      • 12.4.1.1 Improved public access to modern healthcare facilities and advanced genomics research to fuel market growth
    • 12.4.2 JAPAN
      • 12.4.2.1 Well-established healthcare infrastructure and advanced cancer research activities to support market growth
    • 12.4.3 INDIA
      • 12.4.3.1 Presence of large target patient population and high government healthcare expenditure to support market growth
    • 12.4.4 AUSTRALIA
      • 12.4.4.1 High healthcare expenditure to drive adoption of advanced PCR technologies
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Improved medical tourism and prevalence of chronic diseases to propel market growth
    • 12.4.6 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 BRAZIL
      • 12.5.1.1 Growing focus on proteomics and genomics research to drive market
    • 12.5.2 MEXICO
      • 12.5.2.1 Favorable trade agreements to support imports and improve accessibility to PCR instruments
    • 12.5.3 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST & AFRICA
    • 12.6.1 GCC COUNTRIES
      • 12.6.1.1 Advancements in healthcare infrastructure and increased focus on personalized medicines to fuel market growth
    • 12.6.2 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • 13.3 REVENUE ANALYSIS, 2022-2025
  • 13.4 MARKET SHARE ANALYSIS, 2025
    • 13.4.1 PCR INSTRUMENTS MARKET SHARE, BY KEY PLAYER, 2025
    • 13.4.2 PCR REAGENTS AND CONSUMABLES MARKET SHARE, BY KEY PLAYER, 2025
    • 13.4.3 GLOBAL PCR SOFTWARE AND SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 13.5.1 STARS
    • 13.5.2 EMERGING LEADERS
    • 13.5.3 PERVASIVE PLAYERS
    • 13.5.4 PARTICIPANTS
    • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 13.5.5.1 Company footprint
      • 13.5.5.2 Product footprint
      • 13.5.5.3 Application footprint
      • 13.5.5.4 Technique footprint
      • 13.5.5.5 End user footprint
      • 13.5.5.6 Region footprint
  • 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 13.6.1 PROGRESSIVE COMPANIES
    • 13.6.2 RESPONSIVE COMPANIES
    • 13.6.3 DYNAMIC COMPANIES
    • 13.6.4 STARTING BLOCKS
    • 13.6.5 COMPANY BENCHMARKING: STARTUPS/SMES, 2025
      • 13.6.5.1 Detailed list of key startups/SMEs players
      • 13.6.5.2 Competitive benchmarking of key startups/SMEs
  • 13.7 COMPANY VALUATION AND FINANCIAL METRICS, 2025
  • 13.8 PRODUCT/BRAND COMPARISON
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES AND APPROVALS
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 THERMO FISHER SCIENTIFIC INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Services/Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches and approvals
        • 14.1.1.3.2 Deals
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses and competitive threats
    • 14.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Services/Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches and approvals
        • 14.1.2.3.2 Deals
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses and competitive threats
    • 14.1.3 AGILENT TECHNOLOGIES, INC.
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Services/Solutions offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Deals
        • 14.1.3.3.2 Other developments
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses and competitive threats
    • 14.1.4 BIO-RAD LABORATORIES, INC.
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Services/Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses and competitive threats
    • 14.1.5 QIAGEN
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Services/Solutions offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches and approvals
        • 14.1.5.3.2 Deals
        • 14.1.5.3.3 Expansions
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses and competitive threats
    • 14.1.6 DANAHER CORPORATION
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Services/Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product approvals
        • 14.1.6.3.2 Deals
        • 14.1.6.3.3 Expansions
    • 14.1.7 BBOTT
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Services/Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
    • 14.1.8 TAKARA BIO INC.
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Services/Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Product launches
        • 14.1.8.3.2 Deals
    • 14.1.9 ANALYTIK JENA GMBH+CO. KG
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Services/Solutions offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Product launches
        • 14.1.9.3.2 Deals
    • 14.1.10 EPPENDORF SE
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Services/Solutions offered
      • 14.1.10.3 Recent developments
        • 14.1.10.3.1 Product launches and approvals
        • 14.1.10.3.2 Deals
    • 14.1.11 MERCK KGAA
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Services/Solutions offered
        • 14.1.11.2.1 Deals
        • 14.1.11.2.2 Expansions
    • 14.1.12 BIONEER CORPORATION
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Services/Solutions offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Other developments
    • 14.1.13 REVVITY
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Services/Solutions offered
      • 14.1.13.3 Recent developments
        • 14.1.13.3.1 Product launches
        • 14.1.13.3.2 Other developments
    • 14.1.14 BECTON, DICKINSON AND COMPANY
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Services/Solutions offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Product launches and approvals
        • 14.1.14.3.2 Deals
    • 14.1.15 BIOMERIEUX
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Services/Solutions offered
      • 14.1.15.3 Recent developments
        • 14.1.15.3.1 Product launches and approvals
    • 14.1.16 STANDARD BIOTOOLS
      • 14.1.16.1 Business overview
      • 14.1.16.2 Products/Services/Solutions offered
    • 14.1.17 HOLOGIC, INC.
      • 14.1.17.1 Business overview
      • 14.1.17.2 Products/Services/Solutions offered
      • 14.1.17.3 Recent developments
        • 14.1.17.3.1 Product launches
    • 14.1.18 LONZA
      • 14.1.18.1 Business overview
      • 14.1.18.2 Products/Services/Solutions offered
    • 14.1.19 ILLUMINA, INC.
      • 14.1.19.1 Business overview
      • 14.1.19.2 Products/Services/Solutions offered
    • 14.1.20 SANSURE BIOTECH INC.
      • 14.1.20.1 Business overview
      • 14.1.20.2 Products/Services/Solutions offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 PROMEGA CORPORATION
    • 14.2.2 LIMING BIO
    • 14.2.3 TRANSGEN BIOTECH CO., LTD.
    • 14.2.4 DAAN GENE CO., LTD.
    • 14.2.5 BIOBASE GROUP
    • 14.2.6 NIPPON GENETICS EUROPE
    • 14.2.7 STILLA
    • 14.2.8 GENSCRIPT
    • 14.2.9 NEW ENGLAND BIOLABS

15 RESEARCH METHODOLOGY

  • 15.1 RESEARCH DATA
  • 15.2 RESEARCH DESIGN
    • 15.2.1 SECONDARY RESEARCH
      • 15.2.1.1 Key secondary sources
      • 15.2.1.2 Key objectives of secondary research
      • 15.2.1.3 Key data from secondary sources
    • 15.2.2 PRIMARY RESEARCH
      • 15.2.2.1 Key primary sources
      • 15.2.2.2 Key objectives of primary research
      • 15.2.2.3 Key industry insights
      • 15.2.2.4 Breakdown of primaries
  • 15.3 MARKET SIZE ESTIMATION
    • 15.3.1 BOTTOM-UP APPROACH
      • 15.3.1.1 Company revenue estimation approach
      • 15.3.1.2 Customer-based market estimation
      • 15.3.1.3 Top-down approach
      • 15.3.1.4 Primary interviews
    • 15.3.2 GROWTH FORECAST
  • 15.4 DATA TRIANGULATION
  • 15.5 MARKET SHARE ASSESSMENT
  • 15.6 STUDY ASSUMPTIONS
  • 15.7 GROWTH ASSUMPTIONS
  • 15.8 RISK ASSESSMENT
  • 15.9 RESEARCH LIMITATIONS

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 PCR TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS
  • TABLE 2 ADVANTAGES AND DISADVANTAGES OF REAL-TIME POINT-OF-CARE RT-PCR DEVICES
  • TABLE 3 PCR TECHNOLOGIES MARKET: UNMET NEEDS
  • TABLE 4 STRATEGIC FOCUS OF TIER-1/2/3 PLAYERS
  • TABLE 5 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES
  • TABLE 6 PCR TECHNOLOGIES MARKET: ROLE IN ECOSYSTEM
  • TABLE 7 INDICATIVE PRICING OF PCR SYSTEMS, BY KEY PLAYER, 2025
  • TABLE 8 INDICATIVE PRICING OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025 (USD)
  • TABLE 9 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 10 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • TABLE 11 PCR TECHNOLOGIES MARKET: KEY CONFERENCES AND EVENTS, 2026-2027
  • TABLE 12 US ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 13 INNOVATIONS AND PATENT REGISTRATIONS, 2021-2026
  • TABLE 14 KEY COMPANIES IMPLEMENTING AI/GEN AI IN PCR TECHNOLOGIES MARKET
  • TABLE 15 KEY APPLICATIONS AND INDUSTRIAL OUTCOMES ENABLED BY PCR TECHNOLOGIES
  • TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER
  • TABLE 18 PCR TECHNOLOGIES MARKET: UNMET NEED ANALYSIS
  • TABLE 19 US: CLASSIFICATION OF PCR TECHNOLOGY-ASSOCIATED DIAGNOSTIC DEVICES
  • TABLE 20 CANADA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 21 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 24 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 25 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 26 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 27 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 28 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 29 PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 30 PCR TECHNOLOGIES MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 PCR TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 PCR TECHNOLOGIES MARKET FOR SOFTWARE AND SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 33 PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 34 REAL-TIME PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 35 CONVENTIONAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 DIGITAL PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 ONE-STEP RT-PCR VS. TWO-STEP RT-PCR
  • TABLE 38 REVERSE TRANSCRIPTION PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 BENEFITS AND CONSIDERATIONS OF HOT-START PCR TECHNOLOGY
  • TABLE 40 HOT-START PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 MULTIPLEX PCR MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 42 OTHER PCR TECHNIQUES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 44 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 PCR TECHNOLOGIES MARKET FOR GENOTYPING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID DETECTION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 PCR TECHNOLOGIES MARKET FOR GENE EXPRESSION ANALYSIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 PCR TECHNOLOGIES MARKET FOR NUCLEIC ACID SYNTHESIS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 PCR TECHNOLOGIES MARKET FOR GENETIC SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 50 PCR TECHNOLOGIES MARKET FOR ENVIRONMENTAL APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 51 PCR TECHNOLOGIES MARKET FOR STANDARD VALIDATION/VERIFICATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 PCR TECHNOLOGIES MARKET FOR OTHER APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 54 PCR TECHNOLOGIES MARKET FOR HOSPITAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 PCR TECHNOLOGIES MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 PCR TECHNOLOGIES MARKET FOR ACADEMIC AND GOVERNMENT ORGANIZATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 PCR TECHNOLOGIES MARKET FOR PHARMA-BIOTECH COMPANIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 PCR TECHNOLOGIES MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 59 PCR TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 62 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 64 NORTH AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 65 US: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 66 US: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 67 CANADA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 68 CANADA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 69 EUROPE: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 EUROPE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 71 EUROPE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 72 EUROPE: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 73 EUROPE: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 74 GERMANY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 75 GERMANY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 76 FRANCE: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 77 FRANCE: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 78 UK: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 79 UK: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 80 ITALY: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 81 ITALY: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 82 SPAIN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 83 SPAIN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 84 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 85 REST OF EUROPE : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 88 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 89 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 90 ASIA PACIFIC : PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 91 CHINA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 92 CHINA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 93 JAPAN: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 94 JAPAN: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 95 INDIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 96 INDIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 97 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 98 AUSTRALIA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 99 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 100 SOUTH KOREA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 101 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 102 REST OF ASIA PACIFIC: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 103 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 104 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 105 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 106 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 107 LATIN AMERICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 108 BRAZIL: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 109 BRAZIL: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 110 MEXICO : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 111 MEXICO: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 112 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 113 REST OF LATIN AMERICA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 114 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 115 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 116 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 117 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 118 MIDDLE EAST & AFRICA: PCR TECHNOLOGIES MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 119 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 120 GCC COUNTRIES: PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 121 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET, BY PRODUCT, 2024-2031 (USD MILLION)
  • TABLE 122 REST OF THE MIDDLE EAST & AFRICA : PCR TECHNOLOGIES MARKET, BY TECHNIQUE, 2024-2031 (USD MILLION)
  • TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET
  • TABLE 124 PCR TECHNOLOGIES MARKET: DEGREE OF COMPETITION
  • TABLE 125 PCR TECHNOLOGIES MARKET: PRODUCT FOOTPRINT
  • TABLE 126 PCR TECHNOLOGIES MARKET: APPLICATION FOOTPRINT
  • TABLE 127 PCR TECHNOLOGIES MARKET: TECHNIQUE FOOTPRINT
  • TABLE 128 PCR TECHNOLOGIES MARKET: END USER FOOTPRINT
  • TABLE 129 PCR TECHNOLOGIES MARKET: REGION FOOTPRINT
  • TABLE 130 PCR TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES PLAYERS
  • TABLE 131 PCR TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 132 PCR TECHNOLOGIES MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 133 PCR TECHNOLOGIES MARKET: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 134 PCR TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 135 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 136 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 137 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 138 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 139 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 140 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 141 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 142 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 143 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 144 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 145 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 146 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 147 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 148 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 149 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 150 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 151 QIAGEN: COMPANY OVERVIEW
  • TABLE 152 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 153 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 154 QIAGEN: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 155 QIAGEN: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 156 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 157 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 158 DANAHER CORPORATION: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 159 DANAHER CORPORATION: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 160 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 161 ABBOTT: COMPANY OVERVIEW
  • TABLE 162 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 163 ABBOTT: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 164 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 165 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 166 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 167 TAKARA BIO INC.: DEALS, JANUARY 2021-DECEMBER 2024
  • TABLE 168 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW
  • TABLE 169 ANALYTIK JENA GMBH+CO. KG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 170 ANALYTIK JENA GMBH+CO. KG: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 171 ANALYTIK JENA GMBH+CO. KG: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 172 EPPENDORF SE: COMPANY OVERVIEW
  • TABLE 173 EPPENDORF SE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 174 EPPENDORF SE: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 175 EPPENDORF SE: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 176 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 177 MERCK KGAA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 178 MERCK KGAA: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 179 MERCK KGAA: EXPANSIONS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 180 BIONEER CORPORATION: COMPANY OVERVIEW
  • TABLE 181 BIONEER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 182 BIONEER CORPORATION: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 183 REVVITY: COMPANY OVERVIEW
  • TABLE 184 REVVITY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 185 REVVITY: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 186 REVVITY: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 187 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 188 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 189 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 190 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 191 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 192 BIOMERIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 193 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2026
  • TABLE 194 STANDARD BIOTOOLS: COMPANY OVERVIEW
  • TABLE 195 STANDARD BIOTOOLS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 196 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 197 HOLOGIC, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 198 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2026
  • TABLE 199 LONZA: COMPANY OVERVIEW
  • TABLE 200 LONZA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 201 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 202 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 203 SANSURE BIOTECH INC.: COMPANY OVERVIEW
  • TABLE 204 SANSURE BIOTECH INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 205 PROMEGA CORPORATION: COMPANY OVERVIEW
  • TABLE 206 LIMINGBIO: COMPANY OVERVIEW
  • TABLE 207 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 208 DAAN GENE CO., LTD.: COMPANY OVERVIEW
  • TABLE 209 BIOBASE GROUP: COMPANY OVERVIEW
  • TABLE 210 NIPPON GENETICS EUROPE: COMPANY OVERVIEW
  • TABLE 211 STILLA: COMPANY OVERVIEW
  • TABLE 212 GENSCRIPT: COMPANY OVERVIEW
  • TABLE 213 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 214 PCR TECHNOLOGIES MARKET: STUDY ASSUMPTIONS
  • TABLE 215 PCR TECHNOLOGIES MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 PCR TECHNOLOGIES MARKET: SEGMENTS CONSIDERED
  • FIGURE 2 PCR TECHNOLOGIES MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 GLOBAL PCR TECHNOLOGIES MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF PCR TECHNOLOGIES MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN PCR TECHNOLOGIES MARKET, 2025
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN PCR TECHNOLOGIES MARKET DURING FORECAST PERIOD
  • FIGURE 9 NORTH AMERICA TO COMMAND LARGEST MARKET SHARE DURING STUDY PERIOD
  • FIGURE 10 REAGENTS AND CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN ASIA PACIFIC IN 2025
  • FIGURE 11 CHINA TO REGISTER HIGHEST GROWTH RATE FROM 2025 TO 2031
  • FIGURE 12 PCR TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 13 PCR TECHNOLOGIES MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 14 PCR TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 15 PCR TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 16 AVERAGE SELLING PRICE OF CONVENTIONAL PCR INSTRUMENTS, BY KEY PLAYER, 2025
  • FIGURE 17 AVERAGE SELLING PRICE OF PCR TECHNOLOGY-BASED PRODUCTS, BY REGION, 2023-2025
  • FIGURE 18 IMPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • FIGURE 19 EXPORT DATA FOR HS CODE 3822, BY COUNTRY, 2021-2025 (USD THOUSAND)
  • FIGURE 20 TRENDS/DISRUPTIONS INFLUENCING CUSTOMER BUSINESS
  • FIGURE 21 INVESTMENT AND FUNDING SCENARIO, 2019-2023
  • FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023 (USD MILLION)
  • FIGURE 24 PATENTS APPLIED AND GRANTED, 2016-2026
  • FIGURE 25 PCR TECHNOLOGIES MARKET: IMPACT OF AI/GEN AI
  • FIGURE 26 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 27 KEY BUYING CRITERIA FOR TOP FOUR END USERS
  • FIGURE 28 NORTH AMERICA: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 29 ASIA PACIFIC: PCR TECHNOLOGIES MARKET SNAPSHOT
  • FIGURE 30 REVENUE ANALYSIS OF KEY PLAYERS IN PCR TECHNOLOGIES MARKET, 2022-2025
  • FIGURE 31 PCR INSTRUMENTS MARKET SHARE ANALYSIS, 2025
  • FIGURE 32 PCR REAGENTS AND CONSUMABLES MARKET SHARE ANALYSIS, 2025
  • FIGURE 33 PCR SOFTWARE AND SERVICES MARKET SHARE ANALYSIS (2025)
  • FIGURE 34 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 35 PCR TECHNOLOGIES MARKET: COMPANY FOOTPRINT
  • FIGURE 36 PCR TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 37 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 38 YTD TOTAL RETURN AND 5-YEAR STOCK BETA VALUE FOR KEY PCR TECHNOLOGY VENDORS
  • FIGURE 39 PCR TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
  • FIGURE 43 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • FIGURE 44 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT
  • FIGURE 47 TAKARA BIO INC.: COMPANY SNAPSHOT
  • FIGURE 48 EPPENDORF SE: COMPANY SNAPSHOT
  • FIGURE 49 MERCK KGAA: COMPANY SNAPSHOT
  • FIGURE 50 BIONEER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 51 REVVITY: COMPANY SNAPSHOT
  • FIGURE 52 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 53 BIOMERIEUX: COMPANY SNAPSHOT
  • FIGURE 54 STANDARD BIOTOOLS: COMPANY SNAPSHOT
  • FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT
  • FIGURE 56 LONZA: COMPANY SNAPSHOT
  • FIGURE 57 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 58 SANSURE BIOTECH INC.: COMPANY SNAPSHOT
  • FIGURE 59 PCR TECHNOLOGIES MARKET: RESEARCH DATA
  • FIGURE 60 PCR TECHNOLOGIES MARKET: RESEARCH DESIGN
  • FIGURE 61 PCR TECHNOLOGIES MARKET: KEY DATA FROM SECONDARY SOURCES
  • FIGURE 62 PCR TECHNOLOGIES MARKET: KEY PRIMARY SOURCES (DEMAND AND SUPPLY SIDES)
  • FIGURE 63 PCR TECHNOLOGIES MARKET: KEY INSIGHTS FROM INDUSTRY EXPERTS
  • FIGURE 64 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 65 BREAKDOWN OF PRIMARIES: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 66 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 67 PCR TECHNOLOGIES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION
  • FIGURE 68 PCR TECHNOLOGIES MARKET: BOTTOM-UP APPROACH
  • FIGURE 69 PCR TECHNOLOGIES MARKET: TOP-DOWN APPROACH
  • FIGURE 70 DATA TRIANGULATION METHODOLOGY